Elastrin Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $500K

  • Investors
  • 6

Elastrin General Information

Description

Developer of antibody-targeted nanoparticle therapies designed to reverse arterial calcification and restore tissue elasticity. The company utilizes a proprietary platform to deliver active agents directly to damaged elastin fibers, providing targeted chelation and dual-targeted therapies, enabling healthcare sectors to reverse vascular hardening, improve blood flow, and eliminate the burden of cardiovascular disease without systemic side effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 200 C, Patewood Drive
  • Greenville, SC 29615
  • United States
+1 (864)
Primary Industry
Biotechnology
Corporate Office
  • 200 C, Patewood Drive
  • Greenville, SC 29615
  • United States
+1 (864)

Elastrin Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elastrin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 11-Mar-2025 $500K Completed Pre-Clinical Trials
8. Later Stage VC 03-Nov-2023 Completed Pre-Clinical Trials
7. Later Stage VC 08-Apr-2022 Completed Pre-Clinical Trials
6. Seed Round 04-Mar-2021 Completed Pre-Clinical Trials
5. Grant 01-Aug-2019 Completed Pre-Clinical Trials
4. Grant Completed Pre-Clinical Trials
3. Grant 13-Jan-2019 Completed Pre-Clinical Trials
2. Accelerator/Incubator 17-Nov-2018 $25K $25K Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Elastrin’s complete valuation and funding history, request access »

Elastrin Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-2
Seed-1
Seed 550,000 $0.001000 $4.55 $4.55 1x $4.55 12.04%
To view Elastrin’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Elastrin Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibody-targeted nanoparticle therapies designed to reverse arterial calcification and restore tissue elas
Biotechnology
Greenville, SC
6 As of 2026

Novato, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Elastrin Competitors (3)

One of Elastrin’s 3 competitors is Cyclarity Therapeutics, a Venture Capital-Backed company based in Novato, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cyclarity Therapeutics Venture Capital-Backed Novato, CA
Inozyme Pharma Formerly VC-backed Boston, MA
Nectero Therapeutics Venture Capital-Backed Tempe, AZ
You’re viewing 3 of 3 competitors. Get the full list »

Elastrin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elastrin Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Starbloom Capital Venture Capital Minority
Kizoo Technology Capital Venture Capital Minority
National Heart, Lung, and Blood Institute Government
SC Launch Venture Capital Minority
Clemson University University
You’re viewing 5 of 6 investors. Get the full list »

Elastrin FAQs

  • When was Elastrin founded?

    Elastrin was founded in 2017.

  • Where is Elastrin headquartered?

    Elastrin is headquartered in Greenville, SC.

  • What is the size of Elastrin?

    Elastrin has 6 total employees.

  • What industry is Elastrin in?

    Elastrin’s primary industry is Biotechnology.

  • Is Elastrin a private or public company?

    Elastrin is a Private company.

  • What is Elastrin’s current revenue?

    The current revenue for Elastrin is .

  • How much funding has Elastrin raised over time?

    Elastrin has raised $20.2M.

  • Who are Elastrin’s investors?

    Starbloom Capital, Kizoo Technology Capital, National Heart, Lung, and Blood Institute, SC Launch, and Clemson University are 5 of 6 investors who have invested in Elastrin.

  • Who are Elastrin’s competitors?

    Cyclarity Therapeutics, Inozyme Pharma, and Nectero Therapeutics are competitors of Elastrin.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process